Clinical trial
Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single…
NCT00426036 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00426036 |
|---|---|
| Title | Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine |
| Official title | An Open-Label Study in Healthy Subjects and in Patients With Stable Impaired Renal Function to Assess the Effect of Severe Renal Impairment on Licarbazepine Pharmacokinetics and Metabolism After the Single Administration of a 500 mg Licarbazepine Immediate Release (IR) Tablet |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Licarbazepine |
| Enrollment | 12 |
| Start date | Jun 1, 2006 |
| First posted | Jan 24, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | Czechia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: